Генетические аспекты возникновения и особенности течения рака щитовидной железы

Генетические аспекты возникновения и особенности течения рака щитовидной железы

Автор: Коваленко Ю.В., Толстокоров А.С.

Журнал: Саратовский научно-медицинский журнал @ssmj

Рубрика: Хирургия

Статья в выпуске: 3 т.8, 2012 года.

Бесплатный доступ

Одним из практических результатов прогресса, достигнутого в последние годы в исследовании рака, является идентификация нового класса опухолевых маркёров, протоонкогенов, генов-супрессоров опухолей, генов клеточных рецепторов, полиморфных генных вариантов и других функционально значимых сегментов генома, определение которых во многом основано на выявлении аномальных последовательностей ДНК, специфические повреждения которых являются причиной или модифицирующим фактором канцерогенеза

Опухолевые маркёры, протоонкогены, рак щитовидной железы

Короткий адрес: https://sciup.org/14917636

IDR: 14917636

Список литературы Генетические аспекты возникновения и особенности течения рака щитовидной железы

  • Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma/O. Baris, D. Mirebeau-Prunier, F. Savagner [et al.]//Oncogene. 2005. Vol. 24. P. 4155-4161
  • Significannce of biologic aggressiveness and proliferating activity in papillary thyroid carcinoma/K. Kurozumi, K. Nakao, T. Nishida [et al.]//World J. Surg. 1998. Vol. 22, № 12. P. 1237-1242
  • PAX8-Peroxisome Proliferator-Activated Receptor {gamma} (PPAR {gamma}) Disrupts Normal PAX8 or PPAR {gamma} Transcriptional Function and Stimulates Follicular Thyroid Cell Growth/A.Y. Au, С McBride, K. G. Wilhelm [et al.]//Endocrinology. 2006. Vol. 147. P. 367-376
  • A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression/J.M. Cerutti, R. Delcelo, M.J. Amadei [et al.]//J. Clin. Invest. 2004. Vol. 113. P. 1234-1242
  • Riesco-Eizaquirre G., Santisteban P. Molecular biology of thyroid cancer initiation//Clin. Transl. Oncol. 2007. Vol. 9, № 11. P. 686-693
  • Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/РТС mutation-specific gene expression profiles discovered by DNA microarray analysis/T. J. Giordano, R. Kuick, D. G. Thomas [et al.]//Oncogene. 2005. Vol. 24. P. 6646-6654
  • The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells/R. M. Melillo, M. D. Castellone, V Guarino [et al.]//J. Clin. Invest. 2005. Vol. 115. P. 1068-1081
  • Molecular pathology of well-differentiated thyroid carcinomas/M. Sobrinho-Simoes, A. Preto, A. S. Rocha [et al.]//VirchowsArch. 2005. Vol. 447. P. 787-793
  • Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients/P. Siironen, J. Louhimo, S. Nordling [et al.]//Tumour Biol. 2005. Vol. 26, № 2. P. 57-64
  • Biological activity of activating thyroid-stimulating hormone receptor mutants depends on the cellular context/D. Fuhrer, M. D. Lewis, F. Alkhafaji [et al.]//Endocrinology. 2003. Vol. 144. P. 4018-4030
  • Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma/F. Lesueur, M. McKay, J.D. Corbex [et al.]//J.Med. Genet. 2002. Vol. 39, № 4. P. 260-2655
  • RET/РТС and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation/W.Y. Chung, E. Shin, W.I. Yang [et al.]//J. Korean Med.Sci. 2005. Vol. 20, №1. P. 98-104
  • High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RASBRAF signaling pathway in papillary thyroid carcinoma/E.T Kimura, M. N. Nikiforova, Z. Zhu [et al.]//Cancer Res. 2003. Vol.63. P. 1454-1457
  • BRAF (V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas/E. Puxeddu, S. Moretti, R. Elisei [et al.]//J. Clin. Endocrinol. Metab. 2004. Vol.89, №5. P. 2414-2420
  • BRAF mutations are associated with some histologica I types of papillary thyroid carcinoma/V Trovisco, I. Vieira de Castro, P. Soares [et al.]//J. Pathol. 2004. Vol. 202, № 2. P. 247-251
  • Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells/M.N. Nikiforova, J.R. Stringer, R. Blough [et al.]//Science. 2000. Vol. 290. P. 138-141
  • Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer/F. Granja, J. Morari, E. О Morari [etal.]//Cancer Lett. 2004. Vol. 16, №210. P. 151-157
  • GST profiling may be useful in the screening for thyroid nodule malignancy/F. Granja, J. Morari, E.C. Morari [et al.]//Cancer Lett. 2004. Vol. 25, № 209. P. 129-137
  • Shi Y B, Fu L, Hasebe T, Ishizuya-Oka A. Regulation of extracellular matrix remodeling and cell fate determination by matrix metalloproteinase stromelysin-3 during thyroid hormone-dependent post-embryonic development//Pharmacol. Ther. 2007. Vol. 116, №3. P. 391-400
  • Shih A., Davis F. В., Lin H.Y, Davis P. J. Resveratrol induces apoptosis in thyroid cancer cell lines via а МАРК-and p53-dependent mechanism//J. Clin. Endocrinol. Metab. 2002. Vol. 87, № 3. P. 223-232
  • Akslen L.A. Inccreased angiogenesis in papillary thyroidcarcinoma but lack of prognostic importance//Hum. Pathol. 2000. Vol. 31, № 4. P. 439-442
  • Delias O, Loskutoff D. J. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease//Thromb. Haemost. 2005. № 93. P. 631 -640
  • Duffy M.J., Duggan О The urokinase plasminogen activator system: a rich source of tumour markers for the individualized management of patients with cancer//Clin. Biochem. 2004. Vol. 37. P. 541 -548
  • Кушлинский H.E. Клиническая роль системы активации плазминогена в опухолях человека//Молекулярная медицина. 2007. № 1. С. 4-8
  • The angiotensin l-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer/M. P. Ebert, U. Lendeckel, S. Westphal [et al.]//Cancer Epidemiol. Biomarkers Prev. 2005. Vol. 14, № 12. P. 2987-1989
  • Rocken O, Lendeckel U., Dierkes J., Westphal S. The number of lymph node metastases in gastric cancer correlates with the angiotensin l-converting enzyme gene insertion/deletion polymorphism//Clin. Cancer Res. 2005. Vol. 1, № 11. P. 2526-2530.
  • Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk//Cancer Epidemiol. Biomarkers Prev. 2005. Vol. 14, № 9. P. 2143-2146
  • Koh J.T., Biggins J.B. Ligand-receptor engineering and its application towards the complementation of genetic disease and target identification/A. M. Gonzalez-Zuloeta Ladd, A.A. Vasquez, F.A. Sayed-Tabatabaei [et al.]//Curr.Top. Med. Chem. 2005. Vol. 5, № 4. P. 413-420
  • Angiotensin l-converting enzyme gene insertion/deletion polymorphism and endometrial human cancer in normotensive and hypertensive women/M. Freitas-Silva, D. Pereira, О Coelho [et al.]//Cancer Gene Cytogenet. 2004. Vol. 155, № 1. P. 42-46.
  • Chang H. S., Nam КН., Chung W.Y, Park О S. Anaplastic thyroid carcinoma: a therapeutic dilemma//Yonsei Med. J. 2005. Vol. 46, № 6. P. 759-764
  • Angiotensin-converting enzyme gene insertion/deletion polymorphism is associated with risk of oral precancerous lesion in betel quid chewers/F. M. Chung, Y H. Yang, С. H. Chen [et al.]//Br. J. Cancer. 2005. Vol. 93, № 5. P. 602-606
  • Martin M.D., Matrisian L.M. The other side of MMPs: protective roles in tumor progression//Cancer Metastasis Rev. 2007. Vol. 26, № 3-4. P. 717-724
  • Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism/S. Ye, S. Dhillon, S. J. Turner [et al.]//Cancer Res. 2001. Vol. 15, №4. P. 1296-1298.
  • Pepper M.S. Lymphangiogenesis and tumor metastasis: more questions than answers//Lymphology. 2000. Vol. 33, № 4. P. 144-147
  • Johansson N., Ahonen M. Matrix metalloproteinases in tumor invasion//Cell. Mol. Life Sci. 2000. Vol. 20, № 1. P. 5-15.
  • Asingle Nucleotide Polymorphism in the MMP-3 promoter enhances breast cancer susceptibility/G. Ghilardi, M.L. Biondi, M. Caputo [et al.]//Cancer Res. 2002. Vol. 8. P. 3820-3823
  • Bogusiewicz M., Stryjecka-Zimmer M., Szymanski M. Activity of matrix metalloproteinases-2 and -9 in advanced laryngeal cancer//Otolaryngol. Head Neck. Surg. 2003. Vol. 128, № 1. P. 132-136
  • Shiomi T, Okada Y MMP-1 and MMP-7 in invasion and metastasis of human cancers//Cancer Metastasis Rev. 2003. Vol.22. P. 145-152
  • Reichenberger F, Eickelberg O., Wyser O, Perruchoud A. P. Distinct endobronchial expression of matrix-metalloproteinases (MMP) and their endogenous inhibitors in lung cancer//Swiss Med. Wkly. 2001. Vol. 19, № 131. P. 273-279
  • Богатиков А. А. Прогностическое значение клинико-ге-нетических факторов в хирургическом лечении папиллярного рака щитовидной железы: автореф. дис.... канд. мед. наук. СПб., 2010. 27 с.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp